IP Library Granted Patent US 10,752,698
Granted Patent B2
US 10,752,698 · App. 15/526,522 · Granted Aug 25, 2020

Method for generating high affinity antibodies

Inventors: Gang Chen (Yorktown Heights, NY); Robert Babb (River Edge, NJ); James P. Fandl (LaGrangeville, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C07K16/32C07K16/00C07K16/22G01N33/50C07K2317/10C07K2317/92C12N2510/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,752,698
App. No.
15/526,522
Granted
Aug 25, 2020
Kind
B2
Abstract

The present disclosure relates to a method for identifying cells that express antigen-specific antibodies with a high binding affinity for a monomeric antigen. Using fluorescence activated cell sorting, cells expressing high affinity antigen-specific antibodies are selected from a population of immune cells isolated from a mammal that has been immunized with or otherwise exposed to the antigen. Nucleic acids encoding the high affinity antibodies can then be cloned into other lymphoid and non-lymphoid cells where the antibody can be expressed and from which the antibodies can be secreted.

Claims (29)

1. A method for selecting primary antibody-producing cells that express antibodies exhibiting high binding affinity for an antigen of interest, the method comprising:

(a) contacting a population of primary antibody-producing cells that express antibody to an antigen of interest with a low concentration of a monomeric antigen for a time sufficient for the antigen to bind to antibody on the surface of the cells, wherein the low concentration is less than 2 nM;

(b) washing the cells for a period of time to remove unbound antigen; and

(c) collecting cells bound to the antigen, thereby selecting cells expressing high affinity antibodies.

2. The method of claim 1 , wherein the concentration of antigen is between 1 nM and 2 nM.

3. The method of claim 1 , wherein the concentration of antigen is less than 1 nM.

4. The method of claim 1 , wherein cells of the population of cells express antibody that is membrane-bound antibody.

5. The method of claim 1 , wherein the antigen comprises a detectable label.

6. The method of claim 5 , wherein the detectable label is conjugated directly to the antigen.

7. The method of claim 6 , wherein the detectable label is conjugated to antigen via a pair of binding partners.

8. The method of claim 7 , wherein one binding partner of the pair of binding partners is labeled with a detectable label.

9. The method of claim 7 , wherein the pair of binding partners is biotin/streptavidin.

10. The method of claim 5 , wherein the antigen is biotinylated and the biotinylated antigen is contacted with streptavidin comprising the detectable label.

11. The method of claim 10 , wherein cells that bind the biotinylated antigen are contacted with the streptavidin after step b).

12. The method of claim 5 , wherein the detectable label is a fluorescent label.

13. The method of claim 12 , wherein step c) comprises using fluorescence-activated cell sorting to collect cells that bind the antigen.

14. The method of claim 5 , further comprising collecting the cells that bind detectable label to isolate cells that express antibodies of high affinity.

15. The method of claim 1 , wherein the period of time for washing the cells is less than about 60 minutes.

16. The method of claim 1 , wherein said washing the cells for a period of time comprises one (1) wash for about 10 minutes to about 60 minutes total.

17. The method of claim 1 , wherein said washing the cells for a period of time comprises two (2) washes for about 5 minutes to about 30 minutes per wash.

18. The method of claim 1 , wherein the cells collected in step c) are sorted as single cells that express antibodies of high affinity.

19. The method of claim 1 , wherein the primary antibody-producing cells are obtained from spleen, lymph node, peripheral blood and/or bone marrow.

20. The method of claim 1 , wherein the affinity of the antibody is in the range of from about 0.1 pM to about 25 nM (K D ).

21. The method of claim 20 , wherein the affinity of the antibody is from 0.1 nM to 25 nM (K D ).

22. The method of claim 1 , further comprising: isolating antibody-encoding nucleic acid from the cells collected in step (c).

23. The method of claim 22 , further comprising transfecting a host cell with a vector comprising the antibody-encoding nucleic acid; and growing the transfected host cell under conditions to support expression of antibody by the host cell.

24. The method of claim 23 , wherein the vector is an expression vector.

25. The method of claim 24 , wherein the host cell is Chinese hamster ovary (CHO) cell.

26. The method of claim 1 , wherein the cells collected in step c) are sorted into a pool of cells that express antibodies of high affinity.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2017
From: CHEN, GANG; BABB, ROBERT; FANDL, JAMES P.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 043573/0950 →
Continuity (2)
Provisional Application 62079899 · Nov 14, 2014
Related Publication 20170327593A1 · Nov 16, 2017
Cited By (1)
US 12,480,947